Skip to main content

Table 3 Risk of diabetes in patients with atrial fibrillation receiving DOACs and warfarin

From: Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population‐based cohort study

  All patients Women Men Pinteraction
Hazard ratio (95% CI) P Hazard ratio (95% CI) P Hazard ratio (95% CI) P
DOACs vs Warfarin (ref.)
 Apixaban vs Warfarin 0.79 (0.62–1.02) 0.07 1.02 (0.69–1.50) 0.92 0.62 (0.46–0.84) 0.002 0.046
 Dabigatran vs Warfarin 0.69 (0.56–0.86)  < 0.001 0.69 (0.50–0.96) 0.03 0.70 (0.53–0.92) 0.01 0.99
 Rivaroxaban vs Warfarin 0.82 (0.64–1.04) 0.1 0.98 (0.68–1.40) 0.9 0.70 (0.51–0.97) 0.03 0.18
 Apixaban/ Rivaroxaban vs Warfarin 0.80 (0.66–0.99) 0.04 1.00 (0.73–1.37) 0.99 0.66 (0.51–0.86) 0.002 0.048
DOACs vs DOACs (ref.)
 Apixaban vs Dabigatran 1.14 (0.90–1.46) 0.28 1.47 (1.02–2.13) 0.04 0.89 (0.66–1.21) 0.46 0.04
 Rivaroxaban vs Dabigatran 1.18 (0.93–1.50) 0.17 1.41 (1.00–1.99) 0.05 1.01 (0.73–1.39) 0.96 0.17
 Rivaroxaban vs Apixaban 1.03 (0.79–1.35) 0.82 0.96 (0.64–1.43) 0.83 1.13 (0.80–1.60) 0.48 0.54
 Apixaban/ Rivaroxaban vs Dabigatran 1.16 (0.95–1.42) 0.14 1.44 (1.07–1.94) 0.02 0.95 (0.73–1.24) 0.7 0.04